Stockreport

Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights

Evommune, Inc.  (EVMN) 
PDF – Reported positive top-line data from Phase 2a proof-of-concept (POC) trial of EVO301 in atopic dermatitis (AD)– EVO756 on track to report Phase 2b top-line data in chr [Read more]